TT Capital Partners, NovaQuest Capital Management, and Frist Cressey Ventures Invests in InformedDNA

We represented TT Capital Partners (TTCP), NovaQuest Capital Management (NovaQuest) and Frist Cressey Ventures in its recapitalization and growth equity investment in InformedDNA, the nation’s largest provider of genetic services. InformedDNA will use the capital to continue scaling its technology-enabled, genetics expert services, as well as to expand its staff of genetic counselors. Terms of the transaction were not disclosed.

The TTCP and NovaQuest Capital Management deal teams were led by Ryan Thomas and included corporate attorneys Ryan Hoffman, Bo Cook, Gardner Bell and Oliver Peglow. Philip Lewis counseled on tax issues while Shannon Wiley and Whitney Snow advised on healthcare regulatory issues; Felix Dowsley and Vincent Lillegard advised on financing-related matters; Shelley Thomas, Emily Burrows and Stefanie Colletier advised on intellectual property matters; and Kimberly Veirs advised on labor and employment matters. Michael Holley also advised Frist Cressey Ventures in its minority investment.

You Also May Be Interested In:

  • We represented ALS Education, Inc., an education dropout prevention and recovery program, in the sale of its charter school management...
    Client Type: Private Company
  • Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers

    We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company